Finasteride Regulatory Status: US, EU, Canada, UK

How Finasteride Works: The 5-Alpha Reductase Mechanism

Finasteride is a competitive inhibitor of type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT) in prostate tissue, hair follicles, and other androgen-sensitive organs. A single 1 mg dose suppresses serum DHT by approximately 65% to 70%, while the 5 mg dose achieves suppression above 70% within 24 hours 1. That DHT reduction is the pharmacological basis for both approved indications.

In BPH, lower intraprostatic DHT concentrations shrink the gland, reduce urinary obstruction, and decrease the risk of acute urinary retention. The Proscar Long-Term Efficacy and Safety Study (PLESS, N=3,040) showed a 57% reduction in the risk of acute urinary retention and a 55% reduction in the need for surgical intervention over four years compared with placebo 2. In AGA, the same DHT suppression slows miniaturization of terminal hair follicles in the vertex and mid-scalp. Kaufman et al. reported that men on finasteride 1 mg daily for five years maintained a mean increase of 277 hairs in a 5.1 cm² target area from baseline, while placebo-treated men lost 139 hairs over the same period 1.

The drug does not bind the androgen receptor. It has no direct anti-androgenic activity. Its effect is confined to reducing conversion of one androgen to a more potent one.

United States: FDA Approval Timeline

The FDA approved finasteride 5 mg (brand name Proscar, Merck) on June 19, 1992, under NDA 020180 for the treatment of symptomatic BPH 3. That made it the first 5-alpha reductase inhibitor available in the US market.

Five years later, finasteride 1 mg (Propecia, Merck) received FDA approval on December 22, 1997, under NDA 020788 for male androgenetic alopecia 4. The approval relied on two randomized, double-blind, placebo-controlled trials enrolling 1,553 men aged 18 to 41 with mild-to-moderate vertex hair loss 1.

Generic finasteride 5 mg became available after Merck's patent expired in June 2006. Generic finasteride 1 mg followed in 2013 after the expiration of an additional use patent. As of 2026, the FDA Orange Book lists more than 20 approved ANDA holders for both strengths.

Both strengths remain prescription-only. The FDA has not approved finasteride for use in women, and the label carries a pregnancy category X warning due to the risk of genital malformation in a male fetus exposed in utero 5.

Post-Market Safety Actions (US)

In April 2012, the FDA required Merck to revise the Propecia and Proscar labels to include reports of sexual adverse effects (decreased libido, erectile dysfunction, ejaculation disorders) persisting after discontinuation 6. The same safety communication noted data from the Prostate Cancer Prevention Trial (PCPT, N=18,882) and REDUCE trial (N=8,231) indicating an increased incidence of high-grade prostate cancer (Gleason score 8 to 10) in men taking 5-alpha reductase inhibitors, though overall prostate cancer incidence was lower 7. An FDA advisory committee voted in 2011 that the benefit-risk balance remained favorable for BPH.

In 2022, the FDA added depression and suicidal ideation to the Warnings and Precautions section of the label following review of post-marketing reports submitted through the FDA Adverse Event Reporting System (FAERS).

European Union: EMA and National Authorizations

Finasteride entered the EU market through national authorization procedures rather than through the centralized EMA pathway. Proscar 5 mg received its first EU marketing authorization in the early 1990s across multiple member states (France, Germany, the Netherlands, among others), with Propecia 1 mg following in 1998 to 1999 through mutual recognition procedures.

The European Medicines Agency conducted an Article 31 referral on finasteride in 2017 to 2018, specifically reviewing reports of sexual dysfunction and psychiatric disorders (depressed mood, anxiety, suicidal thoughts). The Pharmacovigilance Risk Assessment Committee (PRAC) concluded in June 2018 that the product information should be updated to warn that sexual dysfunction, including after treatment discontinuation, and depressive mood may occur 8. The Committee for Medicinal Products for Human Use (CHMP) endorsed the recommendation. The drug was not withdrawn or restricted.

Generic finasteride has been available in the EU through decentralized procedures since approximately 2009. Multiple generic manufacturers hold marketing authorizations in the reference member states. Finasteride remains prescription-only across all EU member states. No EU country has moved finasteride to over-the-counter status as of May 2026.

The EU Summary of Product Characteristics (SmPC) specifies the same two indications as the US label: BPH (5 mg) and AGA in men (1 mg). Neither indication is approved for women in any EU member state.

United Kingdom: MHRA and the P-Medicine Reclassification

In the UK, Proscar and Propecia hold Marketing Authorizations issued by the Medicines and Healthcare products Regulatory Agency (MHRA). Post-Brexit, the UK operates its own regulatory pathway independent of the EMA.

The most significant regulatory change in the UK came in 2022. The MHRA reclassified finasteride 1 mg from prescription-only medicine (POM) to pharmacy medicine (P) for men aged 18 to 50 with AGA 9. This means that a registered pharmacist can supply finasteride 1 mg after a structured consultation, without a physician prescription. The reclassification does not apply to the 5 mg strength, which remains POM for BPH.

That reclassification was the first of its kind among major regulatory agencies. The pharmacist must confirm the patient is male, within the specified age range, and seeking treatment for male pattern hair loss rather than other causes of alopecia. A referral to a physician is required if the patient reports mood changes, persistent sexual side effects, or breast changes during follow-up.

The UK label mirrors the updated EU warnings on sexual dysfunction, psychiatric symptoms, and the need for patient counseling before initiation.

Canada: Health Canada Approvals

Health Canada approved Proscar 5 mg (DIN 00836117) for BPH in 1992 and Propecia 1 mg (DIN 02242834) for AGA in 1998. Both are classified as Schedule F prescription drugs. Generic finasteride has been available in Canada since the mid-2000s, with numerous Drug Identification Numbers listed in the Drug Product Database.

The Canadian product monograph was updated in 2012 to align with the FDA safety communication regarding persistent sexual adverse effects. A further update in 2021 added warnings about mood alterations and suicidal ideation, consistent with the EMA PRAC recommendation 10.

Health Canada has not authorized finasteride for women. The product monograph carries the same teratogenicity warning present in the US and EU labeling. Finasteride is covered by most provincial drug formularies for the BPH indication (5 mg) but coverage for the AGA indication (1 mg) varies by province and is generally not publicly reimbursed.

Global Patent Status and Generic Access

Merck's original compound patent for finasteride expired in 2006 in the US and between 2004 and 2006 in most other markets. A method-of-use patent specific to AGA treatment expired in the US in 2013. These expirations opened the door for generic competition.

The price difference is substantial. In the US, brand Propecia carries an average wholesale price of roughly $90 to $100 for a 30-day supply, while generic finasteride 1 mg is available for $3 to $15 per month at retail pharmacies, and sometimes under $1 per month through certain discount programs 11. Generic availability has made finasteride one of the least expensive prescription treatments for AGA worldwide.

In developing markets, finasteride is widely available as a generic product. The World Health Organization includes finasteride on the WHO Model List of Essential Medicines for the BPH indication 12.

Comparative Regulatory Positions on Safety Signals

All four regulatory agencies (FDA, EMA/PRAC, MHRA, Health Canada) have reviewed the same core safety signals and reached broadly similar conclusions. None have withdrawn finasteride or restricted its approved indications.

The persistent sexual dysfunction signal has been the most contentious. A systematic review and meta-analysis by Traish et al. (2011) estimated that sexual adverse effects occur in approximately 3.4% to 15.8% of finasteride users, depending on the outcome measured and the study design 13. The Swedish Medical Products Agency reported in their 2018 safety review that the absolute risk of persistent sexual side effects remained low (fewer than 1 in 100 treated patients), though precise incidence is difficult to establish from spontaneous reporting data alone.

The Prostate Cancer Prevention Trial raised a separate concern. While overall prostate cancer incidence fell by 24.8% in the finasteride arm (N=9,060) compared to placebo (N=9,457), high-grade tumors (Gleason 7 to 10) were more frequent: 6.4% vs. 5.1% 7. A long-term follow-up at 18 years found no significant difference in overall survival between the two arms, which led the authors to conclude that the high-grade signal may reflect detection bias rather than true biological promotion of aggressive disease 14.

Regulators have taken a "warn but permit" approach. Every major agency now requires the product label to disclose persistent sexual adverse effects and psychiatric symptoms, but none consider these risks sufficient to override the therapeutic benefit in the approved populations.

Off-Label Use and Regulatory Gaps

Finasteride is used off-label in several populations that no regulator has formally approved. These include:

Women with androgenetic alopecia. Small trials have tested finasteride 2.5 mg to 5 mg daily in postmenopausal women. A study by Iorizzo et al. (2006, N=37) reported improvement in 62% of postmenopausal women treated with finasteride 2.5 mg daily for one year 15. No regulatory agency has approved finasteride for this use. The teratogenicity risk makes prescribing in premenopausal women of childbearing potential a serious medicolegal consideration.

Transgender hormone therapy. Finasteride is sometimes prescribed as an adjunct to estrogen therapy in transgender women to reduce DHT-mediated effects. No specific regulatory approval exists for this indication in any jurisdiction.

Hirsutism in polycystic ovary syndrome. Some clinicians prescribe finasteride 5 mg for hirsutism refractory to oral contraceptives and spironolactone. Again, this use is entirely off-label.

These gaps highlight that regulatory approval often lags behind clinical practice. Physicians prescribing finasteride off-label carry the burden of informed consent regarding both efficacy data and teratogenic risk.

Ongoing Regulatory Activity

Several regulatory developments are in progress or anticipated as of mid-2026. The FDA is conducting a structured benefit-risk assessment of 5-alpha reductase inhibitors under the PDUFA VII commitment, with a public update expected later this year. The MHRA is reviewing two years of post-reclassification pharmacovigilance data for finasteride 1 mg as a pharmacy medicine, which will determine whether the P status is maintained or modified.

The European generic market is seeing new topical formulations of finasteride (0.1% to 0.25% spray solutions) submitted via national procedures in several EU member states. These topical formulations aim to reduce systemic DHT exposure while maintaining local scalp efficacy. A phase III trial by Piraccini et al. (2022, N=458) found that topical finasteride 0.25% produced noninferior hair count increases compared with oral finasteride 1 mg over 24 weeks, with significantly lower serum DHT suppression (30% to 35% vs. 55% to 60%) 16.

The UK's reclassification of finasteride 1 mg to pharmacy supply remains unique among major regulators, and its success or failure may influence similar decisions in Australia (TGA), New Zealand (Medsafe), and other common-law pharmaceutical systems.

Prescribers checking a patient's finasteride regimen should confirm the dose, verify the indication, and document counseling on sexual and psychiatric side effects at every renewal, per the current FDA-mandated Medication Guide and equivalent documents in EU, UK, and Canadian jurisdictions 6.